上海谊众药业股份有限公司 关于出售已回购股份的进展公告

Core Viewpoint - The company, Shanghai Yizhong Pharmaceutical Co., Ltd., has initiated a share repurchase program to maintain company value and protect shareholder interests, with plans to sell the repurchased shares within a specified timeframe [2][3]. Group 1: Share Repurchase Details - The company repurchased a total of 1,274,307 shares from August 26, 2024, to December 25, 2024 [2]. - The repurchased shares will be sold through centralized bidding within twelve months after the announcement of the repurchase results, and any unsold shares will be canceled [2]. Group 2: Sale Plan Progress - The company plans to sell up to 1,274,307 repurchased shares, not exceeding 0.62% of the total share capital, within six months from January 22, 2026, to July 21, 2026 [3]. - Proceeds from the sale will be used to supplement the company's working capital to support research and development projects and daily operations [3]. Group 3: Implementation Status - As of January 31, 2026, the company has not yet sold any of the repurchased shares [4]. - The company is required to disclose the progress of the sale plan within the first three trading days of each month [6]. Group 4: Compliance and Regulations - The sale plan is consistent with previously disclosed plans and complies with relevant regulations, including the Shanghai Stock Exchange's guidelines on share repurchase [6]. - The company will adhere to legal requirements during the sale process and fulfill information disclosure obligations [8].